Phuturdex › Diseases › Thoracic Neoplasms
Drugs in development · updated 30 October 2026
Thoracic Neoplasms: drugs in development
As of 30 October 2026 there are 18 active clinical trials (recruiting or ongoing, phases I–III) on 25 drugs for thoracic Neoplasms. 8 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OlomorasibLY3537982 | III | 1 | NCT06119581 |
| QL2107 | III | 1 | NCT07162883 |
| ElironrasibRMC-6291 | I–II | 2 | NCT06128551 |
| CeralasertibAZD6738 | II | 1 | NCT05941897 |
| MecapegfilgrastimPEG-rhG-CSF, PEG-rhG-GSF | II | 1 | NCT07205536 |
| OleclumabMEDI9447 | II | 1 | NCT06606847 |
| RMC-6236 | I–II | 1 | NCT05379985 |
| YL201 | I–II | 1 | NCT07407933 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CarboplatinCarboplatine, Paraplatin | III | 3 | NCT06119581 |
| PaclitaxelTaxol, Paxlitaxel | III | 2 | NCT04564157 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 2 | NCT07162883 |
| CisplatinCis Platinum, Cisplatine | III | 1 | NCT06119581 |
| NivolumabOpdivo, ONO-4538 | III | 1 | NCT04564157 |
| PemetrexedAxtle®, Pemfexy® | III | 1 | NCT06119581 |
| DurvalumabMEDI4736, Imfinzi® | II | 2 | NCT05941897 |
| SelpercatinibLOXO-292, Retevmo® | I–II | 2 | NCT03157128 |
| AtezolizumabTecentriq, MPDL3280A | I–II | 1 | NCT07407933 |
| AtorvastatinLipitor, Atorvaliq® | II | 1 | NCT07685938 |
| BudesonideTarpeyo®, Eohilia® | II | 1 | NCT03803787 |
| CemiplimabREGN2810, Libtayo® | II | 1 | NCT06917573 |
| DaraxonrasibRasonque® | I–II | 1 | NCT06128551 |
| LisinoprilQbrelis®, Zestril® | II | 1 | NCT07685938 |
| RepotrectinibAugtyro® | I–II | 1 | NCT03093116 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 25 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Non-small-cell lung carcinoma 726 drugs
- Lung neoplasm 348 drugs
- Lung small cell carcinoma 197 drugs
- Colorectal neoplasm 534 drugs
- Melanoma 352 drugs
- Metastasis 493 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Ovarian neoplasm 411 drugs
- Neoplasm 671 drugs
- Breast neoplasm 593 drugs
- Stomach neoplasm 340 drugs
- Pancreatic neoplasm 395 drugs
Broader categories
- Neoplasm 671 drugs
- Bronchial disease 4 drugs
- Respiratory disease 57 drugs
- Carcinoma, Bronchogenic 16 drugs
- Bronchial neoplasm 17 drugs
- Digestive System Diseases 36 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D013899 “Thoracic Neoplasms”.